Li Xiaohui, Gu Wenshen, Liu Yijun, Wen Xiaoyan, Tian Liru, Yan Shumei, Chen Shulin
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People's Republic of China.
Department of Clinical Laboratory Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Cancer Cell Int. 2022 Aug 11;22(1):251. doi: 10.1186/s12935-022-02671-2.
The prognosis of non-small cell lung cancer (NSCLC) with brain metastases (BMs) had been researched in some researches, but the combination of clinical characteristics and serum inflammatory indexes as a noninvasive and more accurate model has not been described.
We retrospectively screened patients with BMs at the initial diagnosis of NSCLC at Sun Yat-Sen University Cancer Center. LASSO-Cox regression analysis was used to establish a novel prognostic model for predicting OS based on blood biomarkers. The predictive accuracy and discriminative ability of the prognostic model was compared to Adjusted prognostic Analysis (APA), Recursive Partition Analysis (RPA), and Graded Prognostic Assessment (GPA) using concordance index (C-index), time-dependent receiver operating characteristic (td-ROC) curve, Decision Curve Analysis(DCA), net reclassification improvement index (NRI), and integrated discrimination improvement index (IDI).
10-parameter signature's predictive model for the NSCLC patients with BMs was established according to the results of LASSO-Cox regression analysis. The C-index of the prognostic model to predict OS was 0.672 (95% CI = 0.609 ~ 0.736) which was significantly higher than APA,RPA and GPA. The td-ROC curve and DCA of the predictive model also demonstrated good predictive accuracy of OS compared to APA, RPA and GPA. Moreover, NRI and IDI analysis indicated that the prognostic model had improved prediction ability compared with APA, RPA and GPA.
The novel prognostic model demonstrated favorable performance than APA, RPA, and GPA for predicting OS in NSCLC patients with BMs.
一些研究对伴有脑转移(BMs)的非小细胞肺癌(NSCLC)的预后进行了研究,但尚未描述将临床特征与血清炎症指标相结合作为一种非侵入性且更准确的模型。
我们回顾性筛选了中山大学肿瘤防治中心初诊为NSCLC且伴有BMs的患者。采用LASSO-Cox回归分析基于血液生物标志物建立预测总生存期(OS)的新型预后模型。使用一致性指数(C-index)、时间依赖性受试者工作特征(td-ROC)曲线、决策曲线分析(DCA)、净重新分类改善指数(NRI)和综合判别改善指数(IDI),将预后模型的预测准确性和判别能力与校正预后分析(APA)、递归划分分析(RPA)和分级预后评估(GPA)进行比较。
根据LASSO-Cox回归分析结果,建立了伴有BMs的NSCLC患者的10参数特征预测模型。该预后模型预测OS的C-index为0.672(95%CI = 0.609 ~ 0.736),显著高于APA、RPA和GPA。与APA、RPA和GPA相比,预测模型的td-ROC曲线和DCA也显示出对OS的良好预测准确性。此外,NRI和IDI分析表明,该预后模型与APA、RPA和GPA相比具有更好的预测能力。
在预测伴有BMs的NSCLC患者的OS方面,新型预后模型表现优于APA、RPA和GPA。